免疫刺激剂在幽门螺杆菌根除治疗中的疗效评价  

Efficacy evaluation of immune-stimulating agents in Helicobacter pylori eradication therapy

作　　者：张中极[1] 

机构地区：[1]江苏省江阴市人民医院胃病专科,江苏江阴214400

出　　处：《实用临床医药杂志》2012年第15期135-137,共3页Journal of Clinical Medicine in Practice

摘　　要：目的观察和评价免疫刺激剂联合三联疗法在幽门螺杆菌(Hp)根除治疗中的临床疗效。方法将150例Hp阳性患者随机分为2组,治疗组给予免疫刺激剂(匹多莫德口服液)联合三联疗法(奥美拉唑+克拉霉素+阿莫西林)治疗,对照组单纯采用三联疗法治疗,观察2组患者的临床疗效。结果治疗组Hp根除率(92.0%)明显高于对照组(64.0%),差异有统计学意义(P<0.01);治疗组症状缓解率(73.3%)显著高于对照组(56.0%),差异有统计学意义(P<0.05);治疗组不良反应发生率(8.0%)低于对照组(17.3%),但差异无统计学意义(P>0.05)。治疗组复发率(21.7%)显著低于对照组(43.8%),差异有统计学意义(P<0.05)。结论免疫刺激剂联合三联疗法可提高Hp根除率、临床症状缓解率、Hp复发率,减少抗生素不良反应,可直接用于根除Hp的一线首次治疗。Objective To observe and evaluate the clinical efficacy of immune stimulant combined with triple therapy in Helicobacter pylori（Hp） eradication therapy.Methods A total of 150 Hp-positive patients were randomly divided into treatment group and control group.The treatment group received immune-stimulating agent（pidotimod oral solution） combined with triple therapy（omeprazole,clarithromycin,and amoxicillin amoxicillin）,and the control group only received triple therapy.The clinical efficacy of the two groups was observed.Results The HP eradication rate in the treatment group（92.0%） was obviously higher than that in the control group（64.0%）（P0.05）.The recurrence rate in the treatment group（21.7%） was obviously lower than that in the control group（43.8%）.Conclusion Immune stimulant combined triple therapy can improve the eradication rate,remission rate of clinical symptoms,recurrence rate of Hp infection,and reduce the adverse reactions of antibiotics.It can be directly used for the first-line treatment of Hp eradication on the first attempt.

关 键 词：免疫刺激剂 HP根除治疗 疗效 

分 类 号：R573[医药卫生—消化系统]